Condition
Efavirenz
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownItraconazole Pharmacokinetic With and Without Efavirenz Using the Capsule Formulation as Part of Talaromycosis Treatment in HIV-infected AdultsNCT04031053 · 2019-06-01
UNKNOWNNeuropsychiatric Side Effects of Efavirenz in Children Living With HIVNCT03227653 · 2017-06-19
COMPLETEDSwitching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological SuppressionNCT03251690 · 2016-10-27
COMPLETEDInfluence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai PatientsNCT02421289 · 2013-04-01
UNKNOWNCommon interventions
Leading sponsors
Trial status mix
COMPLETED2
UNKNOWN2
Phase mix
NA1
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.